Seelos has scheduled a meeting in
'We are truly excited to be working with the EMA to formulate the Sanfilippo study in the EU', said
Additionally, Seelos has submitted to the FDA a protocol for its planned expanded access study for Sanfilippo syndrome type C and D patients as well as type A and B patients who do not meet the Phase IIb/III trial entry criteria.
Seelos continues to pursue its plans to develop SLS-005 in oculopharyngeal muscular dystrophy (OPMD) and is evaluating other potential indications where scientific rationale for studying trehalose exists.
Forward-Looking Statements
Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, among others, those regarding the scheduled meeting with the EMA and any potential outcome of such meeting, the potential for an expanded access study for Sanfilippo syndrome type C and D patients and certain type A and B patients and Seelos' plans to develop SLS-005 in OPMD and other potential indications. These statements are based on Seelos' current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Risks associated with Seelos' business include, but are not limited to, the risk of not successfully executing its clinical studies and not gaining marketing approvals for its product candidates, the risks associated with the implementation of a new business strategy, the risks related to raising capital to fund its development plans and ongoing operations, as well as other factors expressed in Seelos' periodic filings with the
Contact:
Tel: (646) 293-2136
Email: anthony.marciano@seelostx.com
(C) 2020 Electronic News Publishing, source